Bexarotene and systemic disease progression in CTCL?

J Am Acad Dermatol. 2006 Aug;55(2):365-6; author reply 366. doi: 10.1016/j.jaad.2006.01.022.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Bexarotene
  • Disease Progression
  • Humans
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Mycosis Fungoides / drug therapy
  • Reproducibility of Results
  • Risk Factors
  • Sezary Syndrome / drug therapy
  • Tetrahydronaphthalenes / adverse effects*
  • Tetrahydronaphthalenes / therapeutic use

Substances

  • Antineoplastic Agents
  • Tetrahydronaphthalenes
  • Bexarotene